

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Dar Rami</u>  (Last) (First) (Middle) <u>C/O BIOLINERX LTD.</u> <u>2 HAMA'AYAN STREET</u>  (Street) <u>MODI'N L3 7177871</u>  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>03/18/2026</u>	3. Issuer Name and Ticker or Trading Symbol <u>BioLineRx Ltd. [ BLRX ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Employee Stock Option (Right to Buy) <sup>(1)(2)</sup>	10/03/2022	07/03/2032	Ordinary Shares	1,080,000	0.085	D	
Employee Stock Option (Right to Buy) <sup>(1)(3)</sup>	10/03/2023	07/03/2033	Ordinary Shares	360,000	0.081	D	
Employee Stock Option (Right to Buy) <sup>(1)(4)</sup>	10/03/2024	07/03/2032	Ordinary Shares	360,000 <sup>(6)</sup>	0.085	D	
Employee Stock Option (Right to Buy) <sup>(1)(5)</sup>	01/01/2025	08/14/2034	Ordinary Shares	2,055,000 <sup>(6)</sup>	0.052	D	

**Explanation of Responses:**

- Options granted under the 2003 Amended and Restated Share Incentive Plan.
- The grant date of this grant is July 3, 2022. This option grant is fully vested as of this date.
- The grant date of this grant is July 3, 2023. This option grant is fully vested as of this date.
- The grant date of this grant is July 3, 2024. This option grant is fully vested as of this date.
- The grant date of this grant is October 1, 2024. As of this date, 856,200 of the options were vested as of the date of appointment. The remaining 1,198,800 options will vest in 7 equal quarterly installments, subject to the Reporting Person's continued service to the Issuer as of each vesting date.
- To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee.

/s/ Rami Dar

03/31/2026

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.